• Blog
  • Opioid Induced Constipation (OIC) Drug Market Report

    Opioid Induced Constipation (OIC) Drug Market Report

    Opioid Induced Constipation (OIC) Drug Market Report
    Report code - SR1424 Delivery - 2 Weeks
    Get Free Sample |
    Opioid-Induced Constipation (OIC) Drug Market Trends, Dynamics & Market Insights
    See more...

    Impact of COVID-19 on Opioid Induced Constipation (OIC) Drug Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Opioid Induced Constipation (OIC) Drug Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Opioid-Induced Constipation (OIC) Drug Market is estimated to grow from USD 1.7 billion in 2020 to USD 3.2 billion by 2026 at a healthy CAGR of 11.1% during the forecast period.

    Figure: Opioid Induced Constipation (OIC) Drug Market Size, 2020-2026 (USD Billion)

    Opioid-Induced-Constipation-(OIC)-Drug-Market-Forecast

    Wish to get a free sample? Register Here

    What are opioid induced constipation drugs?

    Opioid-Induced Constipation (OIC) drugs are prescribed to patients with acute and chronic non-cancer pain. They reduce the secretion of digestive enzymes which results in opioid-induced constipation with several symptoms such as the bulged abdomen, distention, bloating, and painful defecation due to hard and dry stools.

    Key Players

    Key players operating in the Opioid-Induced Constipation (OIC) Drug market are-

    • AstraZeneca plc (UK)
    • Mallinckrodt Pharmaceuticals (UK)
    • Salix Pharmaceuticals Inc (US)
    • Merck & Co Inc (US)
    • Shionogi & Co Ltd (Japan)
    • Theravance Biopharma Inc (US)
    • Valeant Pharmaceuticals International (Canada)
    • Cosmo Pharmaceuticals SA (Ireland)
    • Daewoong Pharmaceutical (South Korea)
    • C B Fleet Company (US).

    Market Dynamics

    The key factor augmenting the market growth is a rising number of senior patients as these patients use opioid analgesics such as hydromorphone, morphine, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. Moreover, the increasing volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to spur the industry growth during the review period.

    Segments' Analysis

    Drug Type Trends

    Based on drug type, the market has been classified into Mu-opioid receptor antagonists, chloride channel-2 activators, and others. The Mu-opioid receptor antagonists segment accounted for a substantial market share in 2020. This is mainly attributed to the easy availability of several types of products launched by major players which are suitable for various symptoms in the OIC and surge in research activities in the segment, which proliferates the segment growth.

    Regional Trends

    The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly ascribed to the increasing prevalence of various GI disorders among geriatric patients in the US and a steep rise in the consumption of opioids in Canada in past few years. Moreover, the presence of established players in the market and funding for R&D activities further bolsters regional growth.

    COVID-19 Impact on Opioid-Induced Constipation (OIC) Drug Market

    The COVID-19 outbreak positively influenced the growth of the Opioid-Induced Constipation (OIC) Drug market. The pandemic caused added challenges for patients who are having some form of gastrointestinal infection. Due to social distancing, many hospitals have restricted appointments, and they were instead offering patient video conferencing to overcome the limitations of the market growth.

    • What are the key trends in the global Opioid Induced Constipation (OIC) Drug market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Opioid Induced Constipation (OIC) Drug market?
    • What are the key strategies adopted by the major vendors to lead in the global Opioid Induced Constipation (OIC) Drug market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the opioid induced constipation drug market hopes to have the greatest opportunity to convert-

    • Opioid Induced Constipation (OIC) Drug distributors
    • Opioid Induced Constipation (OIC) Drug suppliers
    • Opioid Induced Constipation (OIC) Drug manufacturers
    • Hospitals
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The opioid induced constipation drug market is expected to witness an impressive growth of 11.1% CAGR in the coming years.

    AstraZeneca plc (UK), Mallinckrodt Pharmaceuticals (UK), Salix Pharmaceuticals Inc (US), Merck & Co Inc (US), Shionogi & Co Ltd (Japan), Theravance Biopharma Inc (US), Valeant Pharmaceuti-cals International (Canada), Cosmo Pharmaceuticals SA (Ireland), Daewoong Pharmaceutical (South Korea), and C B Fleet Company (US) are among the key players in the opioid induced constipation drug market.

    The opioid induced constipation drug market size is expected to reach USD 3.2 billion in the foreseeable future.

    The Mu-opioid receptor antagonists segment accounted for a substantial share in the opioid constipation drug market in 2020.

    North America is expected to remain dominant in the opioid induced constipation drug market in the next five years.

    Opioid Induced Constipation (OIC) Drug distributors, Opioid Induced Constipation (OIC) Drug suppliers, Opioid Induced Constipation (OIC) Drug manufacturers, Hospitals, Government bodies are the target audience in the opioid induced constipation drug market.

    //